GSK returns gemifloxacin rights
Executive Summary
GlaxoSmithKline will return worldwide rights to quinolone antibiotic Factive (gemifloxacin) to development partner LG Chemicals Investments. Factive was deemed "not approvable" by FDA at the end of 2000 (1"The Pink Sheet" July 30, 2001, p. 20)...
You may also be interested in...
GSK Has Generalized Anxiety For Paxil, Augmented Patent For Augmentin
GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.